Recruiting
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
NCT07551596· Phase 2· National Cancer Institute (NCI)· Source
Contact: Kanwal P. Raghav (principal investigator)
Recruiting
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
NCT07621614· Phase 2· Children's Oncology Group· Source
Contact: Najat C. Daw (principal investigator)
Not yet recruiting
Data Collection For Patients With Sickle Cell Disease
NCT07911618· M.D. Anderson Cancer Center· Source
Contact: Kebriaei,Partow Kebriaei, MD
Not yet recruiting
Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With
NCT07819474· M.D. Anderson Cancer Center· Source
Contact: Ashley M Holder, MD
Not yet recruiting
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
NCT07783594· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Dai Chihara, MD
Not yet recruiting
Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome
NCT07780565· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Abhishek Maiti, MBBS
Not yet recruiting
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
NCT07349641· Phase 2· National Cancer Institute (NCI)· Source
Contact: Roni N. Wilke
Recruiting
Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract
NCT07789119· M.D. Anderson Cancer Center· Source
Contact: Bryon Lee, MD
Recruiting
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
NCT07804186· Phase 3· IDEAYA Biosciences· Source
Contact: Mohamed Gouda
Recruiting
Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions
NCT07743476· M.D. Anderson Cancer Center· Source
Contact: Omran Saifi, MD
Recruiting
Prospective Observational Study Of Geniculate Artery Embolization For Symptomatic Knee Osteoarthritis In A Cancer Population
NCT07807943· M.D. Anderson Cancer Center· Source
Contact: Nicolas J Cardenas, MD
Recruiting
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
NCT07428616· Phase 2· Exelixis· Source
Contact: Exelixis Clinical Trials
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566· Phase 2· Black Diamond Therapeutics, Inc.· Source
Contact: Mohammed Nassfi
Recruiting
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
NCT06498648· Phase 1/2· National Cancer Institute (NCI)· Source
Contact: Neeta Somaiah (principal investigator)
Recruiting
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
NCT07356245· Phase 2· Ohio State University Comprehensive Cancer Center· Source
Contact: Clinical Trial Registration Help Lines
Recruiting
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
NCT07281430· National Cancer Institute (NCI)· Source
Contact: Elizabeth Y. Chiao
Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432· Phase 1/2· Vironexis Biotherapeutics Inc.· Source
Contact: Christine Tran
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· Phase 3· NRG Oncology· Source
Contact: Comron Hassanzadeh (principal investigator)
Active, not recruiting
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
NCT06730100· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· Phase 3· NRG Oncology· Source
Contact: Ethan B. Ludmir (principal investigator)
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· Phase 3· Canadian Cancer Trials Group· Source
Contact: Paul Corn (principal investigator)
Recruiting
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373· Phase 2· Swedish Orphan Biovitrum· Source
Contact: Study Physician
Recruiting
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· Phase 3· Children's Oncology Group· Source
Contact: Najat C. Daw (principal investigator)
Recruiting
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
NCT06364410· Phase 1· National Cancer Institute (NCI)· Source
Contact: Funda Meric-Bernstam (principal investigator)
Active, not recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· Phase 3· NRG Oncology· Source
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· Phase 3· National Cancer Institute (NCI)· Source
Contact: Paolo Strati (principal investigator)
Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817· Phase 2· Children's Oncology Group· Source
Contact: Najat C. Daw (principal investigator)
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· Phase 3· National Cancer Institute (NCI)· Source
Contact: Carlos Torrado (principal investigator)
Active, not recruiting
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)
NCT06611540· National Cancer Institute (NCI)· Source
Active, not recruiting
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
NCT06498661· National Cancer Institute (NCI)· Source
Recruiting
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· Phase 3· Canadian Cancer Trials Group· Source
Contact: Tsuyoshi Konishi (principal investigator)
Recruiting
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
NCT06064097· Phase 2· National Cancer Institute (NCI)· Source
Contact: Najat C. Daw (principal investigator)
Recruiting
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
NCT06102902· Phase 1· National Cancer Institute (NCI)· Source
Contact: Salvador Alonso Martinez (principal investigator)
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296· Phase 3· National Cancer Institute (NCI)· Source
Contact: Najat C. Daw (principal investigator)
Active, not recruiting
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT05564403· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
NCT05711615· Phase 1· National Cancer Institute (NCI)· Source
Contact: Michael S. Nakazawa (principal investigator)
Active, not recruiting
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
NCT05761171· Phase 2· Children's Oncology Group· Source
Recruiting
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
NCT05691465· Phase 2· National Cancer Institute (NCI)· Source
Contact: Ana Aparicio (principal investigator)
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· Phase 3· NRG Oncology· Source
Contact: Karen E. Hoffman (principal investigator)
Active, not recruiting
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
NCT05702645· Children's Oncology Group· Source
Contact: Najat C. Daw (principal investigator)
Active, not recruiting
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
NCT05836571· Phase 2· National Cancer Institute LAO· Source
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Vicente Valero (principal investigator)
Active, not recruiting
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
NCT05724108· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194· Phase 3· Children's Oncology Group· Source
Recruiting
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT05372640· Phase 1· National Cancer Institute (NCI)· Source
Contact: Sarina A. Piha-Paul (principal investigator)
Recruiting
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
NCT05879367· Phase 1· Orbus Therapeutics, Inc.· Source
Contact: Carlos Kamiya Matsuoka, MD
Recruiting
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996· Phase 3· NRG Oncology· Source
Contact: Julianna Bronk (principal investigator)
Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· Phase 3· National Cancer Institute (NCI)· Source
Contact: Najat C. Daw (principal investigator)
Active, not recruiting
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
NCT05419011· Phase 2· National Cancer Institute (NCI)· Source
Showing 50 of 170.